Trial Profile
Effect of RANKL Inhibition on UV-induced Immunosuppression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Immunosuppression; Skin cancer
- Focus Pharmacodynamics
- 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2013 New trial record